8-K: iTeos Therapeutics and GSK Terminate Belrestotug Development Program After Disappointing Trial Results

iTeos Therapeutics and GSK halt the development of belrestotug following unfavorable interim results from the GALAXIES Lung-201 study, prompting iTeos to initiate a strategic review to maximize shareholder value.

Summary

• iTeos Therapeutics and GSK have decided to terminate their collaboration on the belrestotug development program.
• This decision follows disappointing topline interim results from the GALAXIES Lung-201 Phase 2 study, which assessed belrestotug in combination with dostarlimab for non-small cell lung cancer.
• The study did not meet established criteria for clinically meaningful improvements in progression-free survival.
• An interim analysis of the GALAXIES H&N-202 Phase 2 trial also showed a trend below the meaningful threshold for objective response rate in head and neck squamous cell carcinoma.
• As a result, all belrestotug-containing cohorts are ending, including the GALAXIES Lung-301 Phase 3 trial.
• iTeos is initiating a strategic review to explore alternatives for maximizing shareholder value.
• The company emphasizes its strong balance sheet and commitment to disciplined execution.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the termination of a key development program and the need for a strategic review. However, the company's strong balance sheet and commitment to shareholder value provide some positive aspects.

Positives

• iTeos has a strong balance sheet, which positions them well to pursue opportunities that maximize shareholder value.
• The company is committed to disciplined execution as it explores strategic alternatives.
• iTeos will share the data with the scientific community at an upcoming medical meeting to advance the understanding of immuno-oncology and TIGIT.

Negatives

• The GALAXIES Lung-201 study did not meet established criteria for clinically meaningful improvements in progression-free survival.
• An interim analysis of the GALAXIES H&N-202 Phase 2 trial showed a trend below the meaningful threshold for objective response rate.
• The termination of the belrestotug development program and collaboration with GSK represents a setback for iTeos.

Risks

• Volatility and uncertainty in the capital markets for biotechnology companies could impact iTeos' ability to execute its strategic review.
• There is a risk that iTeos may not be able to identify opportunities to maximize shareholder value or execute on such opportunities on attractive terms or timing.
• Capital preservation strategies undertaken may not be effective.

Future Outlook

iTeos will promptly evaluate a full range of strategic alternatives to unlock the value of its assets and maximize shareholder value.

Management Comments

• 'We are truly disappointed by the results from GALAXIES Lung-201,' said Michel Detheux, Ph.D., president and chief executive officer of iTeos.
• 'Following the analysis of the TIGIT data generated to-date with GSK, we have made the mutual decision to discontinue development of all ongoing TIGIT studies.'
• 'We are grateful to all patients, caregivers, and investigators involved in the GALAXIES studies and believe it is important to share these data with the scientific community at an upcoming medical meeting in order to advance our collective understanding of immuno-oncology and TIGIT.'
• 'However, given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets,' continued Dr. Detheux.
• 'With a strong balance sheet and a commitment to disciplined execution, we are well positioned to pursue opportunities that maximize shareholder value.'

Industry Context

The termination of this collaboration reflects the challenges and risks inherent in drug development, particularly in the competitive immuno-oncology space. The failure of the belrestotug combination to demonstrate sufficient efficacy highlights the need for rigorous clinical trials and careful evaluation of therapeutic strategies. Other companies in the immuno-oncology space include Roche (developing tiragolumab, another TIGIT inhibitor), and Bristol Myers Squibb (developing relatlimab, a LAG-3 inhibitor).

Comparison to Industry Standards

• The GALAXIES Lung-201 trial aimed to improve upon existing treatments for PD-L1 high non-small cell lung cancer, where dostarlimab monotherapy is already a standard of care.
• The failure to achieve clinically meaningful improvements in progression-free survival suggests that the belrestotug + dostarlimab combination did not meet the efficacy bar set by existing therapies and other investigational agents in this space.
• Competitors like Roche with their TIGIT inhibitor tiragolumab, have also faced challenges in demonstrating clear clinical benefit in certain lung cancer settings, highlighting the difficulty in developing effective TIGIT-targeting therapies.
• The decision to terminate the belrestotug program is similar to other instances where pharmaceutical companies have discontinued development of drug candidates that fail to meet pre-defined efficacy criteria in clinical trials.

Stakeholder Impact

• Shareholders will be impacted by the termination of the belrestotug program and the strategic review.
• Employees may be affected by any restructuring or changes resulting from the strategic review.
• Patients who were participating in the belrestotug clinical trials will need to be managed appropriately by GSK and investigators.

Next Steps

• iTeos will share the data from the GALAXIES studies with the scientific community at an upcoming medical meeting.
• iTeos will conduct a targeted review of strategic alternatives to maximize shareholder value.
• GSK will communicate with investigators, institutional review boards, ethics committees, and health authorities about next steps for appropriate management of currently enrolled patients.

Key Dates

Keywords

iTeos Therapeutics, GSK, belrestotug, GALAXIES Lung-201, TIGIT, immuno-oncology, non-small cell lung cancer, strategic review, shareholder value, clinical trial, termination, collaboration